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Abstract
Background: Sin3A is an evolutionarily conserved transcriptional repressor which regulates gene expression as part
of the multi-protein Sin3 repressive complex. It functions as a scaffold upon which proteins with enzymatic activity
dock, including chromatin modifying histone deacetylases. Although regulation of transcription by Sin3A has been
studied in detail, little is understood about the function of Sin3A in cancer cells. We previously showed that Sin3A
is expressed in breast cancer cells and is a repressor of estrogen receptor-alpha (ERa, ESR1) gene expression. Here,
we expand our previous studies to elucidate the function of Sin3A in the control of gene expression and growth
of breast cancer cells.
Results: Analysis of gene expression following knockdown of Sin3A revealed changes in both basal and regulated
gene transcription. Genes of known importance in breast cancer and estrogen signaling, including ERBB2, PGR,
MYC, CLU, and NCOA2, were among those identified as Sin3A-responsive. The mechanism of Sin3A action varied
among genes and was found to be mediated through both HDAC1/2 -dependent and -independent activities.
Loss of Sin3A inhibited breast cancer cell growth by increasing apoptosis without affecting cell cycle progression.
Analysis of both ERa-positive and ERa-negative cell lines revealed that the effects of Sin3A on growth were cell-
type specific, as Sin3A expression promoted maximum growth of only the ERa-positive cells, and, notably, Sin3A
protein itself was increased by estrogen. Further gene expression experiments revealed that Sin3A repressed
expression of key apoptotic genes, including TRAIL, TRAILR1, CASP10, and APAF1,i nE R a-positive, but not ERa-
negative, cell lines, which could provide a mechanistic explanation for cell-type differences in growth.
Conclusions: This study identifies Sin3A as a regulator of gene expression, survival, and growth in ERa-positive
breast cancer cells. Sin3A regulates the transcription of genes involved in breast cancer and apoptosis and acts
through multiple mechanisms not limited to histone deacetylase function. These findings reveal previously
undescribed functions of Sin3A in breast cancer and provide evidence for an important role of this transcriptional
repressor in ERa-positive tumor cell growth.
Background
Appropriate regulation of genes is important in main-
taining normal cell growth, and disruption of gene regu-
lation is associated with human cancer. Changes in gene
expression can distinguish types of breast tumors and
predict response to therapies [1-3]. Tremendous effort,
therefore, has been devoted to dissecting pathways that
regulate transcription. For example, understanding the
mechanisms of gene activation by estrogen receptor-
alpha (ERa) was foundational in the development of
hormonal therapy [4]. Interestingly, microarray analyses
on estrogen-treated breast cancer cells show that the
number of repressed genes is greater than or near the
number of activated genes [5-8]. Although these experi-
ments show that estrogen-mediated repression of genes
is clearly biologically important, the mechanisms
responsible for repression are not fully understood. We
previously showed that the Sin3A transcriptional repres-
sor protein is a regulator of estrogen-induced repression
of the ERa gene, ESR1, in breast cancer cells [9].
Furthermore, it was found that Sin3A and ERa exist in
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suggested that Sin3A may play a broader role in ERa-
positive breast cancer cells.
The role of Sin3A in breast cancer is virtually unex-
plored, but studies suggest that Sin3A is important in
normal growth and may be a player in other neoplastic
model systems. Homozygous deletion of Sin3A in mice
is embryonic lethal, demonstrating that Sin3A serves
essential developmental functions [10,11]. Studies
using conditional Sin3A knockout in mouse embryonic
fibroblasts (MEFs) find that Sin3A deletion leads to
decreased proliferation and increased apoptosis of cells
[10,11]. In cancer models, Sin3A function is less clear.
Lymphoma and sarcoma cell lines derived from primary
tumors arising in a p53
-/- background exhibit prolifera-
tive arrest and increased apoptosis upon Cre-mediated
deletion of Sin3A, suggesting that Sin3A has oncogenic
functions [11]. However, another report suggests that
Sin3A functions as a tumor suppressor in non-small cell
lung cancer (NSCLC), as down-regulation of Sin3A
mRNA occurs in several cases of NSCLC [12]. These
few reports with disparate findings highlight a funda-
mental lack of understanding of the role of Sin3A in
growth and cancer.
At the molecular level, Sin3A functions as the scaf-
folding component of the multi-protein Sin3 repressor
complex that mediates transcriptional repression of sev-
eral genes. The Sin3 complex was identified in yeast but
is conserved in species through mammals [13,14]. The
characteristic catalytic activity associated with Sin3A is
histone deacetylation via its interactions with HDAC1/2
[15,16]. Additional components of the complex consist
of SAP18/30, which stabilize the Sin3A-HDAC interac-
tion, and RbAp46/48, which anchor the Sin3 complex
on nucleosomes [15-17]. Sin3A does not possess intrin-
sic DNA-binding activity, so it must be targeted via
interaction with other DNA-bound factors. Interactions
for numerous DNA-binding factors and Sin3A have
been identified, including Mad, p53, MeCP2, NRSF,
CTCF, and ERa as examples [9,18-22]. Sin3A can also
interact with other enzymatic proteins, including those
capable of histone methylation, DNA methylation, chro-
matin remodeling, and N-acetylglucoseamine transferase
activity [20,23-28].
In this report, we expand our previous findings and
identify the function of Sin3A in gene expression, survi-
val, and growth of breast cancer cells. Gene expression
analysis identified a specific subset of Sin3A-responsive
genes that were regulated by both HDAC1/2-dependent
and -independent mechanisms. Importantly, decreased
Sin3A expression led to an increase in apoptosis and
increased expression of several apoptotic genes, which
translated into attenuation of cell growth of ERa-posi-
tive and not ERa-negative breast cancer cells. This
study identifies Sin3A as an essential regulator of
growth and survival of ERa-positive breast cancer cells,
which may have important translational implications for
breast cancer patients.
Results
Sin3A regulates basal expression and estrogen-induced
responses of specific genes in breast cancer cells
Sin3A is a conserved multifunctional repressor protein
present in organisms from yeast to mammals that func-
tions by regulating gene transcription [17]. Our lab
previously showed that Sin3A regulated the estrogen-
induced repression of the ERa gene, ESR1, in the MCF7
breast cancer cell line [9]. To identify other genes regu-
lated by Sin3A, MCF7 cells were transfected with a
scrambled (scr.) negative control or Sin3A siRNA fol-
lowed by treatment with vehicle ethanol (EtOH) or 10
nM 17-b-estradiol (estrogen, E2). Knockdown of Sin3A
protein and mRNA by Sin3A siRNA were validated by
western blot and quantitative reverse transcriptase real-
time PCR (qRT-PCR), respectively (Figure 1A and 1B;
the band for the Sin3A protein at the molecular weight
of 145 kDa is marked with an asterisk). As an initial
approach to identify Sin3A-regulated genes, a prelimin-
ary screen was performed of 84 genes that were identi-
fied based on their importance to breast cancer and
estrogen signaling using a SABiosciences RT
2 Profiler
PCR array. From this screen, 26 genes, including those
that were and those that were not changed by Sin3A
knockdown, were selected for validation by qRT-PCR in
three independent experiments.
Expression data were analyzed for regulation by
Sin3A, resulting in two groups of genes shown in
Table 1: Sin3A responsive and Sin3A non-responsive.
Sin3A responsive genes were those whose basal level
(shown in bold) or estrogen response (shown in bold
italic) were significantly (p < 0.05) changed in the pre-
sence of Sin3A siRNA compared to control scrambled
transfected cells. For basal gene regulation by Sin3A,
statistical analysis identified a 1.75 fold change as a
cutoff for significant regulation. This resulted in eight
Sin3A-responsive genes, all of which showed an
increase in basal expression in the presence of Sin3A
siRNA, in agreement with its role as a repressor of
transcription. Graphs of qRT-PCR data from the three
genes whose basal levels increased greatest with Sin3A
knockdown, C3, CLU,a n dERBB2,a r es h o w ni nF i g u r e
1C, along with an example of a gene whose levels did
not change, TOP2A. For identifying genes whose estro-
gen responses were altered by Sin3A knockdown, any
significant change in the response was allowed, result-
ing in four total genes. Sin3A siRNA prevented signifi-
cant estrogen-induced repression of both ESR1 and
NCOA2; ESR1 regulation by Sin3A had been shown
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Page 2 of 14previously by our lab [9]. The estrogen-induced activa-
tion of MYC and PGR were significantly increased in
the presence of Sin3A siRNA, consistent with the loss
of a transcriptional repressor. Graphs of qRT-PCR data
from these genes are shown in Figure 1D, along with
TFF1 whose estrogen response was not changed with
Sin3A knockdown. The basal levels of the genes in Fig-
ure 1D did not change significantly (NCOA2,1 . 3 4±
0.13; MYC, 1.24 ± 0.24; PGR, 0.88 ± 0.17; TFF1,1 . 4 7±
0.35), and data are graphed as fold changes to highlight
the magnitude of the estrogen response. Genes on the
right-hand side of Table 1, Sin3A non-responsive, were
those that did not statistically change either at the basal
level or in the magnitude of their estrogen-response
with Sin3A siRNA. These results identify a specific sub-
set of genes regulated by Sin3A in breast cancer cells
and show that Sin3A mediates both basal and regulated
gene expression.
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Figure 1 Sin3A controls basal levels and estrogen-induced responses of genes in breast cancer cells. MCF7 cells were transfected with
scrambled (scr.) negative control or Sin3A siRNA, followed by treatment with vehicle control ethanol (EtOH) or 10 nM 17-b-estradiol (estrogen,
E2) for four hours. (A) Knockdown of Sin3A protein was confirmed by western blot analysis. The band specific for Sin3A, which is a 145 kDa
protein, is marked with an asterisk. The blot was reprobed with b-actin for the loading control. (B) Knockdown of SIN3A mRNA was also verified
using quantitative reverse transcriptase real-time PCR (qRT-PCR), with ribosomal protein P0 serving as the housekeeping normalization gene. RNA
levels were calculated relative to the scrambled ethanol sample. Data are from four independent experiments with error bars showing the
standard error of the mean. Student’s t tests were performed comparing corresponding scrambled and Sin3A siRNA samples, *p < 0.05. (C) qRT-
PCR data, regulation of basal levels of genes, C3, CLU, ERBB2, and TOP2A. Experiments were performed and data calculated as above. (D) qRT-PCR
data, regulation of estrogen responses of genes, NCOA2, MYC, PGR, and TFF1. Experiments were performed as above. RNA levels were calculated
for each siRNA group relative to the corresponding ethanol-treated sample. Student’s t tests were performed comparing estrogen responses in
the presence of scrambled versus Sin3A siRNA for MYC and PGR, and determining significant repression of NCOA2,* p < 0.05.
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through HDAC1/2-dependent and-independent
mechanisms
The enzymatic function characteristically associated with
Sin3A is histone deacetylation via its core interactions
with HDAC1 and HDAC2 [16]. However, several studies
have shown that this function can be expanded by add-
ing alternative catalytic components onto the Sin3A
platform [20,23-28]. To gain mechanistic insight into
Sin3A target gene regulation, siRNAs directed against
HDAC1 and HDAC2 were used to establish whether
changes observed in gene expression in Figure 1C and
1D were mediated via Sin3A’s associated core histone
deacetylase activity. MCF7 cells were transfected with
scrambled negative control, HDAC1, or HDAC2 siRNA,
followed by treatment with vehicle ethanol or estrogen.
Experiments also included a double HDAC1 and
HDAC2 knockout since both are present in the Sin3A
complex. Knockdown of HDAC1 and HDAC2 protein
and mRNA levels were verified by western blot and
qRT-PCR analysis (Figure 2A and 2B). Although modest
regulation of the proteins by the opposite siRNA was
observed, the qRT-PCR data showed specific regulation
at the transcript level by respective HDAC siRNAs.
Genes from Figure 1 (C 3 ,C L U ,E R B B 2 ,N C O A 2 ,
MYC, and PGR) which were regulated by Sin3A were
analyzed for changes in expression in the presence of
decreased HDAC1 and HDAC2 levels. C3, whose basal
levels increased in response to Sin3A siRNA (Figure
1C), also increased with the loss of HDAC1 or HDAC2
by siRNA (Figure 2C). In contrast, the levels of CLU,
whose basal levels also increased in response to Sin3A
siRNA, were not increased by any of the HDAC siR-
NAs, even in the double HDAC1 and HDAC2 sample
(Figure 2C). ERBB2 showed similar results to CLU (data
not shown). For regulated responses, the estrogen-
induced repression of NCOA2 was reversed when both
HDAC1 and HDAC2 were decreased (Figure 2D), simi-
lar to the reversal of repression observed with Sin3A
siRNA (Figure 1D). Conversely, none of the HDAC siR-
NAs significantly affected the level of estrogen-induced
activation of the MYC gene (Figure 2D) or PGR (data
not shown). In sum, the loss of HDAC1 and HDAC2
increases C3 and NCOA2,b u tn o tCLU, ERBB2, MYC,
or PGR, providing evidence that C3 and NCOA2 are
repressed in breast cancer cells by the HDAC1/2 com-
ponents of the Sin3A repressive complex. These data
establish that changes mediated by Sin3A in both basal
and estrogen responses of genes involve HDAC1/2-
dependent and -independent mechanisms and are gene
specific.
Loss of Sin3A promotes apoptosis of breast cancer cells
but does not affect cell cycle progression
Gene expression studies described above showed that
loss of Sin3A affected a specific subset of genes involved
in breast cancer by both increases in the basal level and
modulation of estrogen responses. Furthermore, some
mechanisms of regulation involved the HDAC1/2 activ-
ity of the core Sin3A complex (C3, NCOA2), while
others involved alternative capabilities (CLU, MYC).
Together, this suggested that Sin3A was a master scaf-
folding protein whose broad effects on genes may trans-
late into an effect on cell growth. Few studies have been
conducted on the role of Sin3A in growth of mamma-
lian cells, and these few reports have suggested conflict-
ing roles for Sin3A in cancer [11,12].
Flow cytometry analysis was performed on Sin3A
knockdown cells to determine the role of Sin3A in cell
cycle progression of breast cancer cells. MCF7 cells
were transfected with scrambled or Sin3A siRNA and
t r e a t e dw i t ho rw i t h o u te s t r o g e nf o r7 2o r9 6h o u r s .A t
72 hours, there was no difference in the cell cycle distri-
bution, determined by Hoescht dye intensity, of
scrambled and Sin3A siRNA cells treated with vehicle
ethanol (Figure 3A). Similarly, there was no difference
in the cell cycle distribution of cells transfected with
scrambled or Sin3A siRNA and treated with estrogen.
As expected, estrogen treatment resulted in an increase
in the percentage of cells in the S/G2/M phases and a
subsequent decrease in G0/G1 phases [29]. Similar
results were found with the 96 hour samples, shown in
the right panel of Figure 3A, indicating that Sin3A is
not involved in cell cycle progression of MCF7 cells.
Knockdown of Sin3A under these conditions was veri-
fied and is shown in Figure 4B.
Table 1 Sin3A regulation of genes associated with breast
cancer or estrogen receptor signaling
Sin3A Responsive Sin3A Non-responsive
C3 CCND1
CDH1 CCNG2
CDKN1A HMGB1
CLU KRT18
ERBB2 KRT19
GATA3 MAP2K7
MUC1 NCOA3
SERPINA3 NME1
ESR1* PIN1
MYC SERPINB9
NCOA2 TFF1
PGR TGFA
TOP2A
TP53
bold = significant (p < 0.05) increase in basal level of gene by Sin 3A siRNA
bold italic = significant (p < 0.05) change in estrogen response of gene by
Sin3A siRNA.
* = previously identified [9].
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Figure 2 Changes in gene expression by Sin3A are mediated through HDAC1/2-dependent and -independent pathways. MCF7 cells
were transfected with scrambled (scr.), HDAC1, HDAC2, or a combination of HDAC1 and HDAC2 siRNA, followed by treatment with ethanol
(EtOH) or 10 nM estrogen (E2) for four hours. (A) Knockdown of HDAC1 and HDAC2 proteins was confirmed by western blot analysis, and the
blot was reprobed with a-tubulin for the loading control. (B) Knockdown of HDAC1 and HDAC2 mRNA was also verified using qRT-PCR, with
ribosomal protein P0 serving as the housekeeping normalization gene. RNA levels are calculated relative to the scrambled ethanol sample. Data
are from three independent experiments with error bars showing the standard error of the mean. Student’s t tests were performed comparing
corresponding scrambled and HDAC1 or HDAC2 siRNA samples, *p < 0.05. (C) qRT-PCR data, regulation of basal levels of genes, C3 and CLU.
Experiments were performed and data calculated as above. (D) qRT-PCR data, regulation of estrogen responses of genes, NCOA2 and MYC.
Experiments were performed as above. RNA levels were calculated for each siRNA group relative to the corresponding ethanol-treated sample.
Student’s t tests were performed comparing estrogen responses in the presence of scrambled versus HDAC siRNAs, *p < 0.05. ns = not
significant.
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neously for Annexin V staining to assess the level of
cellular apoptosis. At the 72 hour time point, there
was no difference in apoptosis of scrambled and Sin3A
siRNA transfected cells treated with vehicle ethanol
(Figure 3B). Estrogen treatment in control transfected
cells decreased the level of apoptosis compared to
ethanol (first bar versus third bar in Figure 3B). How-
ever, this level of apoptosis was significantly increased
with loss of Sin3A (third bar versus fourth bar in Fig-
u r e3 B ) .B y9 6h o u r s ,t h e r ew a sas i g n i f i c a n ti n c r e a s e
in apoptosis in Sin3A siRNA knockdown cells both in
the presence and absence of estrogen. This identifies
Sin3A as a prosurvival factor in MCF7 cells that pro-
tects against apoptosis.
Sin3A is required for maximum growth of ERa-positive
breast cancer cells
Cell growth assays were performed to determine if the
observed increase in apoptosis by Sin3A knockdown
was sufficient to attenuate growth of breast cancer cells.
Since the increase in apoptosis at 96 hours occurred
both in the presence and absence of estrogen (Figure
3B), the growth of ERa-negative (MDA-MB-231 and
H s 5 7 8 T )a sw e l la sE R a-positive (MCF7 and T47D) cell
lines was analyzed. Cells were transfected with either
the negative control scrambled or Sin3A siRNA, treated
with vehicle ethanol or estrogen, and the number of live
cells was counted every 24 hours by trypan blue exclusion
(Figure 4). MCF7 cells transfected with the scrambled
negative control grew steadily in the presence of estrogen,
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Figure 3 Loss of Sin3A increases apoptosis but does not affect the cell cycle of breast cancer cells. MCF7 cells were transfected with
scrambled negative control or Sin3A siRNA and treated with vehicle ethanol or 10 nM estrogen (E2) for 72 or 96 hours. Samples were analyzed
simultaneously by flow cytometry for (A) cell cycle distribution and (B) annexin V, indicative of apoptotic cells. Data are from three independent
experiments with error bars showing the standard error of the mean. To determine statistical significance of the findings in (B), student’s t tests
were performed comparing corresponding scrambled and Sin3A siRNA samples, *p < 0.05.
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Figure 4 Sin3A is required for maximum growth of ERa-positive, but not ERa-negative, breast cancer cells.E R a-positive (A, B) MCF7
and (C, D) T47D cells, or ERa-negative (E, F) MDA-MB-231 and (G, H) Hs578T cells, were transfected with either scrambled (scr.) negative
control or Sin3A siRNA. Cells were then treated with vehicle ethanol (EtOH) or 10 nM estrogen (E2). Cells from each group were harvested at
daily intervals, and the number of live cells was determined by trypan blue exclusion and counting. Error bars show the standard error of the
mean of three independent experiments. Lysates from 72 and 96 hour time points were subjected to western blot analysis to confirm efficient
knockdown of Sin3A (B, D, F, H). Blots were reprobed for ERa and the loading control, b-actin. To determine significance of loss of Sin3A on
estrogen-induced growth of cells in (A) and (C), student’s t tests were performed comparing scrambled and Sin3A siRNA samples at each time
point, *p < 0.05.
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group, consistent with the fact that this is an estrogen-
dependent cell line (Figure 4A). Notably, a significant
decrease in estrogen-induced growth of MCF7 cells was
exhibited by those transfected with Sin3A siRNA. MCF7
cells transfected with the Sin3A siRNA but treated with
ethanol also tended to have lower cell numbers than the
corresponding scrambled control, but data were not statis-
tically significant. T47D cells, another ERa-positive cell
line, also exhibited significant attenuation of estrogen-
induced growth in the presence of Sin3A siRNA (Figure
4C). The growth defect was not as dramatic as that
observed in MCF7 cells. It is of note that knockdown of
Sin3A protein, shown by Western blot analysis in Figure
4D, was also less efficient in the T47D cells. In contrast to
the ERa-positive cell lines, ERa-negative MDA-MB-231
and Hs578T cells grew at the same rate in the presence
and absence of Sin3A siRNA or estrogen (Figure 4E and
4G). These data provide evidence that Sin3A is required
for maximum growth of ERa-positive MCF7 and T47D
cells but not ERa-negative MDA-MB-231 and Hs578T
cells.
Western blot analyses in Figure 4B, D, F, and 4H con-
firmed that Sin3A was decreased and could not account
for different dependencies on Sin3A for growth in ERa-
positive versus ERa-negative cell lines. Interestingly,
western blot analysis revealed a robust estrogen-induced
increase in Sin3A protein levels in control transfected
MCF7 cells at both 72 and 96 hours (Figure 4B). This
increase was also observed in T47D cells, albeit to a les-
ser extent (Figure 4D). Data from earlier time points of
four hours estrogen treatment did not show this
increase in Sin3A, suggesting that it is a long-term or
secondary response (Figure 1A and 5C). Further estro-
gen time course western blot experiments showed that
Sin3A protein levels increased by 24 hours of estrogen
treatment in MCF7 cells, and this was sustained at a
similar level out to 96 hours (Additional File 1A). The
increase in Sin3A protein was independent of effects on
transcription of SIN3A mRNA (Additional File 1B).
Estrogen treatment did not affect the levels of SIN3A
mRNA at any time point, but estrogen did decrease the
levels of ESR1 as a positive control for estrogen respon-
siveness (Additional File 1C) [9,30]. The observation
that high levels of Sin3A protein are maintained with
long-term estrogen treatment further supports its role
in promoting survival of ERa-positive cells.
Sin3A differentially represses expression of key apoptotic
genes in ERa-positive versus ERa-negative breast cancer
cells
Data in Figure 3 suggested that Sin3A affected growth
of ERa-positive cells by regulation of apoptosis and not
cellular proliferation. To provide mechanistic insight
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Figure 5 Loss of Sin3A increases expression of apoptotic genes
differentially in ERa-positive and ERa-negative cell lines. (A)
MCF7 or (B) MDA-MB-231 cells were transfected with scrambled
(scr.) negative control or Sin3A siRNA, followed by treatment with
vehicle control ethanol (EtOH) or 10 nM estrogen (E2) for four
hours. qRT-PCR was performed for the indicated apoptotic gene,
with ribosomal protein P0 serving as the housekeeping
normalization gene. RNA levels were calculated relative to the
scrambled ethanol sample. Data are from a minimum of three
independent experiments with error bars showing the standard
error of the mean. Student’s t tests were performed comparing
corresponding scrambled and Sin3A siRNA samples, *p < 0.05. (C)
Knockdown of Sin3A protein was also confirmed by western blot
analysis in each cell line. The blot was reprobed with b-actin for the
loading control.
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formed to identify Sin3A-regulated apoptotic genes. MCF7
cells were transfected with scrambled or Sin3A siRNA and
treated with ethanol or estrogen, as in Figure 1. Several
apoptotic genes were analyzed, including those involved in
both the extrinsic death receptor and the intrinsic mito-
chondrial stress signaling pathways [31]. Genes involved in
the extrinsic death receptor pathway that were significantly
increased upon loss of Sin3A in MCF7 cells were the
apoptotic-inducing ligand TRAIL (also known as TNFSF10
or APO2L), one of its receptors TRAILR1 (also termed
TNFRSF10A, APO2,o rDR4), mediators TRAF4 and
TRADD, and CASP10 (Figure 5A and Additional File 2A).
Other genes implicated in extrinsic death signaling that
were tested but not significantly altered by Sin3A knock-
down were TNF ligand, death receptors TNFRSF25 (also
called APO3 or DR3)a n dFAS,a n dt h eFADD mediator
(data not shown). Three genes involved in the intrinsic
mitochondrial stress signaling apoptotic pathway were also
significantly increased with loss of Sin3A in MCF7 cells -
APAF1, BNIP3L,a n dCASP9 (Figure 5A and Additional
File 2A). Notably, CASP9 was repressed by estrogen treat-
ment, and this repression was reversed in the presence of
Sin3A siRNA (Additional File 2A). Expression of another
key mitochondrial stress gene, BCL2, was not responsive
to Sin3A (data not shown).
Regulation of apoptotic genes was also determined in
ER-negative MDA-MB-231 cells. qRT-PCR analysis was
performed on genes from cells transfected with Sin3A
siRNA and found that the majority of apoptotic genes
were repressed by Sin3A in MCF7 cells, but not MDA-
MB-231 cells (Figure 5B and Additional File 2B). Specifi-
cally, TRAIL, TRAILR1, TRAF4, CASP10,a n dAPAF1 were
not significantly altered by loss of Sin3A in MDA-MB-231
cells (Figure 5B). Three genes, TRADD, BNIP3L,a n d
CASP9, were significantly increased in MDA-MB-231 cells
transfected with Sin3A siRNA, but to a lower level than
MCF7 cells (Additional File 2B). Western blot analysis in
Figure 5C again confirmed that Sin3A levels were effi-
ciently decreased in both cell lines and could not be the
reason for the disparate gene regulation. Together, these
data show that Sin3A differentially regulates the expres-
sion of apoptotic genes in ERa-positive MCF7 cells and
ERa-negative MDA-MB-231 cells, which may selectively
influence the growth and survival of the ERa-positive sub-
type of breast cancer.
Discussion
Previous studies had suggested a role for Sin3A in
growth of normal and neoplastic cells, but the function
of Sin3A in breast cancer had not been fully explored
[10,11]. Prior research from our lab identified Sin3A as
a regulator of ERa gene, ESR1,e x p r e s s i o na n df o u n da n
estrogen-responsive interaction between ERa and Sin3A
[9]. This led us to further determine Sin3A regulation of
gene expression and growth in breast cancer cells.
We find that Sin3A regulates a subset of genes in ERa-
positive MCF7 cells through both HDAC1/2-dependent
and -independent activities. Maximum growth and survi-
val of ERa-positive MCF7 and T47D cells requires
expression of Sin3A. Interestingly, we also find that
estrogen causes an increase in Sin3A protein levels in
ERa-positive cells, suggesting the involvement of Sin3A
in a feedback circuit regulating estrogen-dependent
growth of breast cancer cells. Further, Sin3A represses
important apoptotic genes in ERa-positive cell lines, con-
sistent with our finding that decreased Sin3A levels leads
to cellular apoptosis.
This study identifies the transcriptional repressor,
Sin3A, as a necessary survival factor in ERa-positive
breast cancer cells. Our data further support the idea
that Sin3A promotes growth and survival of cells pro-
posed in previous studies [10,11]. Together, these results
raise the intriguing possibility that gene repression is as
important of a determinant for cell growth as gene acti-
vation, as Sin3A primarily functions as a repressor.
Other chromatin modifying repressor proteins, including
the MTA components of the Mi-2/NuRD complex and
EZH2, are also associated with breast cancer growth and
progression [32-35]. Our identification of Sin3A as a
prosurvival factor is further interesting in that it high-
lights the importance of estrogen-mediated survival of
breast cancer cells. Sin3A knockdown increased apopto-
sis but had no effect on the cell cycle (Figure 3). Estro-
gen is commonly viewed as a mitogenic agent that
increases growth of breast cancer cells through cell
cycle progression, but our data support the notion that
estrogen-mediated repression of apoptosis also has a
large impact on overall growth of cells [29,36].
Clinical trials for HDAC inhibitors in breast cancer
treatment, such as vorinostat, are still in early phases
and often involve patients with advanced disease
[37-40]. These studies have seen only partial efficacy
that often increases when in combination with other
agents, such as chemotherapy, and there are often issues
of toxicity [37-40]. Our data suggest that developing
therapeutic agents to target the scaffolding component
of HDAC-complexes, such as Sin3A, may be of value,
particularly because Sin3A affected only a subset of
genes, but its loss still caused cell death. An agent that
could disrupt Sin3A would target both its HDAC-
dependent and -independent activities, possibly expand-
ing the efficacy beyond that of HDAC inhibitors. Other
reports support the finding that Sin3A has both
HDAC1/2-dependent and -independent capabilities. For
example, in stem cells, Sin3A is the key member of the
Sin3 complex involved in the regulation of NANOG
gene expression, not HDAC1/2 [41]. Several studies
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methylases (Smyd2, Set1/Ash2, and ESET), DNA methy-
lation proteins (MeCP2), chromatin remodeling enzymes
(ISWI, Brg1, hBrm, and BAF155), and O-linked N-
acetylglucosamine transferase (OGT), demonstrating
that Sin3A has the potential to serve as an integrator of
broad transcriptional and epigenetic changes in cells
[20,23-28]. Furthermore, in vitro transcription reactions
on reconstituted nucleosomal templates find that addi-
tion of the HDAC inhibitor, trichostatin A (TSA),
abolishes Sin3A-mediated repression of an acetylated
histone H3 template, but not acetylated histone H4 tem-
plate [42]. This in vitro experiment shows that Sin3A,
even in the absence of other repressor molecules and
enzymatic proteins, possesses some intrinsic HDAC1/2-
independent capabilities.
Our data show that loss of Sin3A increases apoptosis of
ERa-positive MCF7 cells (Figure 3). Upon further
mechanistic experiments, we find that several genes with
known roles in apoptosis are increased with Sin3A
knockdown. This suggests that Sin3A normally represses
their expression in MCF7 cells to aide in preventing
apoptosis, and subsequently, promote cell growth. The
apoptotic gene targets we identified fall into both the
extrinsic death receptor and intrinsic mitochondrial
apoptotic signaling pathways [31]. Interestingly, we find
that Sin3A regulates genes involved in all steps of the
extrinsic pathway in MCF7 cells - ligands, death recep-
tors, adaptors, and caspases (Figure 5A and Additional
File 2A) [43]. Specifically, levels of the TRAIL ligand, and
its receptor, TRAILR1, are increased in MCF7 cells with
Sin3A siRNA. TRAIL is a member of the tumor necrosis
factor (TNF) superfamily of cytokines which can induce
apoptosis by binding to extracellular domains of one of
its receptors, which includes TRAILR1, a member of the
TNF receptor superfamily [44-46]. Death receptors
further use interactions with intracellular adaptor pro-
teins to mediate signals from the extracellular environ-
ment, and loss of Sin3A increased levels of both TRADD
and TRAF4 adaptors [47,48]. Lastly, we identify CASP10
as a Sin3A-responsive gene. In addition to caspase 8, cas-
pase 10 has been shown to act as an initiator caspase in
the death receptor signaling pathway, which can lead to
activation of downstream executioner caspases to cause
apoptosis [49].
Three genes connected to the intrinsic mitochondrial
apoptotic-inducing pathway are also regulated by Sin3A
in MCF7 cells - APAF1, CASP9, and BNIP3L (Figure 5A
and Additional File 2A). The involvement and connec-
tion of Apaf-1 and caspase 9 in stress-induced apoptosis
has been studied in great detail. Briefly, cellular stress
stimulates release of cytochrome c from the mitochon-
dria where it can then bind to Apaf-1, inducing
conformational changes, ATP hydrolysis, and multimeri-
zation of Apaf-1 [50]. The complex, referred to as the
“apoptosome”, then recruits and activates procaspase 9,
and active caspase 9 can cleave executioner caspases to
cause apoptosis [51,52]. Finally, BNIP3L (also known as
NIX) is a proapoptotic member of the Bcl-2 family of
proteins that function upstream of the apoptosome to
regulate the release of cytochrome c from the mitochon-
dria [53,54]. Our findings that Sin3A regulates key genes
from both the death receptor and mitochondrial stress
apoptotic-inducing pathways emphasize the importance
of this transcriptional repressor.
Our data find that Sin3A differentially regulates the
expression of the apoptotic genes discussed above in
ERa-positive (MCF7) and ERa-negative (MDA-MB-231)
cell lines. TRAIL, TRAILR1, TRAF4, CASP10,a n d
APAF1 increase upon Sin3A knockdown in MCF7, but
not MDA-MB-231, breast cancer cells (Figure 5). Three
genes, TRADD, BNIP3L,a n dCASP9,i n c r e a s ei nb o t h
cell lines with loss of Sin3A, demonstrating that Sin3A
possesses some overlapping gene regulation between
breast cancer cell lines, as may be expected (Additional
File 2). However, it is of note that the increase seen in
these three genes upon Sin3A knockdown is greater in
the MCF7 cells. Differences in apoptotic gene regulation
by Sin3A in ERa-subtypes can mechanistically explain
the discrepancies seen in effects of Sin3A on cell
growth. Induction of apoptotic genes in the ERa-posi-
tive MCF7, and not ERa-negative MDA-MB-231 cells,
could lead to increases in apoptosis and a resulting
decrease in cell growth, as we observe. Furthermore,
Sin3A protein itself is increased by estrogen in the ERa-
positive breast cancer cell lines, discussed below.
T oo u rk n o w l e d g e ,t h i si so n eo ft h ef i r s ts t u d i e st o
identify a regulator of Sin3A levels - estrogen. Most stu-
dies concerning Sin3A have focused on its ability to reg-
ulate expression of other genes, and little knowledge
exists about how levels of Sin3A itself are modulated.
Another study has shown that Sin3A can be sumoylated
by TOPORS, but other modulators of Sin3A are vir-
tually unknown [55]. We observe an estrogen-induced
increase in Sin3A protein levels that occurs independent
of effects on Sin3A mRNA, demonstrating that regula-
tion of Sin3A occurs via nongenomic actions (Addi-
tional File 1). This suggests that differences in Sin3A
expression would not be found in microarray studies,
possibly explaining why the role of Sin3A in breast can-
cer has not been appreciated until now. The mechanism
by which estrogen treatment increases Sin3A protein
levels is likely via a secondary effect since elevated levels
are not seen before 24 hours (Figure 1A and 5C). Differ-
ent ERa-positive cell types also seem to have a greater
dependency on Sin3A levels for survival and growth than
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protein in MCF7 than T47D cells, and subsequently, a
greater effect of Sin3A on growth of MCF7 cells (Figure
4).
While this manuscript was under revision, another
group published that the Sin3 complex represses the
ERa gene, ESR1,i nE R a-negative breast cancer cell
lines [56]. Consistent with this finding, we showed
Sin3A regulation of estrogen-induced repression of
ESR1 in MCF7 cells [9]. However, unlike the other
publication, we did not observe reexpression of either
ESR1 mRNA (data not shown) or ERa protein (Figure
4F) in MDA-MB-231 in our current studies. These dis-
crepancies may be due to different experimental condi-
tions and techniques. Importantly, the authors in [56]
disrupted Sin3A and Sin3B function by using the Sin3
interaction domain (SID) of the MAD protein, while
our experiments focused only on Sin3A. Additionally,
the SID from MAD may participate in other protein
interactions beyond the Sin3 proteins. Together, these
reports suggest that components besides Sin3A are
necessary to mediate the repression of ESR1 in ERa-
negative cells.
Finally, our data show several converging points
between Sin3A and the estrogen signaling pathway. As
described above, estrogen increases protein levels of
Sin3A, suggesting a feedback loop to control estrogen-
dependent growth. Our previous report shows that
Sin3A controls expression of the ERa gene itself, ESR1,
and Sin3A can interact with ERa in ERa-positive breast
cancer cells [9]. We further show here that Sin3A con-
trols expression of NCOA2, a member of the p160 coac-
tivator family involved in mediating ERa transcriptional
activation (Figure 1D) [57]. The estrogen-induced acti-
vation of PGR, which encodes the progesterone receptor
(PR), also increases upon Sin3A knockdown (Figure
1D). PR status is often used as a marker of estrogen sen-
sitivity and predictor of response to endocrine therapy
in breast cancer [58,59]. Additionally, knockdown of
Sin3A only prevents growth of ERa-positive MCF7 and
T47D cells, not ERa-negative MDA-MB-231 and
Hs578T cells, further supporting the notion that compo-
nents intrinsic to the ERa signaling pathway are
involved in mediating the ability of Sin3A to promote
survival.
Conclusions
This is one of the first studies to analyze the role of the
Sin3A transcriptional repressor protein in breast cancer.
We find that Sin3A regulates the expression of several
genes important in breast cancer and estrogen signaling,
and these effects are mediated through both HDAC1/2-
dependent and -independent mechanisms of Sin3A. Our
findings show that Sin3A is a prosurvival protein that
promotes growth of ERa-positive breast cancer cells by
preventing apoptosis through repression of key proapop-
totic genes. These findings suggest that Sin3A may be a
new therapeutic target, and identification of an agent
that could disrupt Sin3A may be effective in controlling
survival of ERa-positive tumors.
Methods
Cell Culture and Hormone Treatments
MCF7, MDA-MB-231, and Hs578T cells were main-
tained at 37°C and 10% CO2 in Dulbecco’sm o d i f i e d
Eagle’s medium (DMEM; Mediatech, Inc., Manassas, VA,
USA) with phenol red and L-glutamine, supplemented
with 10% fetal bovine serum (FBS; Biowest, Miami, FL,
USA), 100 units/ml penicillin, and 100 μg/ml streptomy-
cin (GIBCO/Invitrogen, Carlsbad, CA, USA). T47D cells
were maintained at 37°C and 5% CO2 in RPMI 1640
medium with phenol red and L-glutamine (GIBCO), sup-
plemented with 10% FBS, penicillin, and streptomycin as
above. For hormone treatments, all cell lines were incu-
bated at 37°C and 5% CO2 for at least three days in the
media described above but without phenol red and
containing six-times charcoal dextran stripped FBS. 17-
b-estradiol (estrogen, E2; Steraloids, Inc., Newport, RI,
USA) was added to a final concentration of 10 nM in all
experiments for the length of time indicated in the fig-
ures. Ethanol (EtOH) vehicle control was 0.1% in all
samples.
Transfection of siRNA
One day prior to transfection, cells were plated in 10 cm
plates at a density of 2 × 10
6 cells in antibiotic free
media. 800 pmol of siRNA was diluted in Lipofectamine
reagent (Invitrogen) and Opti-MEM (GIBCO) and added
to appropriate plates for five hours. Three days later, cells
were transfected with siRNA again as above in order to
achieve maximum silencing. siRNA duplexes for Sin3A,
HDAC1, HDAC2, and a scrambled negative control were
p r e d e s i g n e da n dp u r c h a s e df r o mS i g m a( S a i n tL o u i s ,
MO, USA).
RNA Isolation and Quantitative RT-PCR
RNA isolation and quantitative reverse transcriptase
real-time PCR (qRT-PCR) were carried out as previously
detailed [9]. Primer sequences are available upon
request. Ribosomal protein P0 mRNA was used as the
internal control. Relative mRNA levels were calculated
using the ΔΔCt method [60]. For initial screening of
candidate Sin3A-regulated genes, two complimentary
trial RT
2 Profiler Human Breast Cancer and Estrogen
Receptor Signaling PCR arrays were used (SABiosciences
now a Qiagen company, Frederick, MD, USA).
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Western blot analysis was carried out as previously
described [61]. The primary antibodies used in this
study were Sin3A (K-20, sc-994, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), ERa (VP-E613, Vector
Laboratories, Burlingame, CA, USA), HDAC1 (H-11, sc-
8410, Santa Cruz), HDAC2 (C-8, sc-9959, Santa Cruz),
b-actin (A5441, Sigma), and a-tubulin (DM1A, CP06,
Calbiochem, San Diego, CA, USA).
Cell Growth Assays
Cells were transfected with scrambled or Sin3A siRNA as
detailed above, changing the media to phenol-red free
media the day before the second transfection. The day
after the second transfection, cells were harvested and pla-
t e di n6 - w e l lp l a t e sa tad e n s i t yo f4×1 0
5 live cells, as
determined by trypan blue exclusion and counting on a
hemacytometer. Cells were then treated with either 10 nM
E2 or EtOH. At 24 hour intervals, cells were harvested and
resuspended in media. The number of live cells at each
time point was determined by hemacytometer counting
and trypan blue exclusion, taking the average of two
counts for each sample in each experiment.
Flow Cytometry for Cell Cycle and Apoptosis Analysis
Knockdown of Sin3A and hormone treatments were
performed as described above. 72 and 96 hours post-
treatment, media and cells were harvested and diluted
to 1 × 10
5 cells in 1 ml of media. Hoescht (Invitrogen)
was added at 10 μg/ml to the cells, and samples were
incubated for 30 minutes at 37°C. Cells were spun down
and resuspended in 100 μl of annexin binding buffer (10
mM HEPES, 140 mM NaCl, and 2.5 mM CaCl2, pH 7.4)
containing Hoescht. 5 μl of the annexin V- Alexa Fluor
647 conjugate (Invitrogen) was added to the cell suspen-
sion and incubated for 15 minutes at room temperature.
After the incubation, an additional 400 μl of annexin
binding buffer was added, followed by propidium iodide
(Sigma) to a concentration of 5 μg/ml. Dye intensities of
10,000 events were measured on the LSRII machine
from BD Biosciences (San Jose, CA, USA) equipped
with a UV laser. Apoptosis levels were analyzed using
FlowJo software (Tree Star, I n c . ,A s h l a n d ,O R ,U S A ) ,
and cell cycle data were analyzed using ModFit software
(Verity Software House, Topsham, ME, USA).
Statistical Analysis
Error bars in all figures are the standard error of the
mean of a minimum of three independent experiments.
Statistics were performed using OrginLab (OrginLab
Corp., Northampton, MA, USA), with the exact test
described in the corresponding figure legend. Data were
considered significant if p < 0.05 and are indicated in
the figures by asterisks.
Additional material
Additional file 1: Estrogen regulates protein levels of Sin3A in
ERaα-positive breast cancer cells. (A) MCF7 cells were treated with
ethanol for 96 hours or 10 nM estrogen (E2) for the indicated length of
time. Cell lysates were analyzed for Sin3A and bβ-actin protein
expression by western blot. (B, C) MCF7 cells were treated as in (A), and
RNA was isolated and reverse transcribed. Quantitative reverse
transcriptase real-time PCR (qRT-PCR) was performed to determine the
expression pattern of (B) SIN3A and (C) ESR1. Data are calculated relative
to the ethanol-treated control, using ribosomal protein P0 as the
housekeeping gene for normalization. Error bars show the standard error
of the mean of three independent experiments.
Additional file 2: Additional apoptotic genes regulated by Sin3A in
breast cancer cell lines. (A) MCF7 or (B) MDA-MB-231 cells were
transfected with scrambled (scr.) negative control or Sin3A siRNA,
followed by treatment with vehicle control ethanol (EtOH) or 10 nM
estrogen (E2) for four hours. qRT-PCR was performed for the indicated
apoptotic gene, with ribosomal protein P0 serving as the housekeeping
normalization gene. RNA levels were calculated relative to the scrambled
ethanol sample. Data are from a minimum of three independent
experiments with error bars showing the standard error of the mean.
Student’s t tests were performed comparing corresponding scrambled
and Sin3A siRNA samples, *p < 0.05.
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